Implantica Launches RefluxStop® in U.S. Market at Foregut Society Meeting
Implantica AG has initiated the U.S. market launch of its RefluxStop® device following recent FDA approval. The medical technology company presented the device at the American Foregut Society's 2026 Annual Meeting, where it received positive attention from leading surgeons.
Medical technology company Implantica AG has commenced the U.S. market launch of its RefluxStop® device. The launch event took place at the American Foregut Society (AFS) 2026 Annual Meeting in Washington D.C., where the device garnered positive reception from leading surgeons and gastroenterologists.
RefluxStop® recently received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA). The device is designed for the treatment of gastroesophageal reflux disease (GERD), a condition affecting approximately 78 million Americans. Unlike traditional surgical procedures that encircle the esophagus, RefluxStop® aims to restore the natural anatomy and physiology of the esophagus without encirclement, potentially minimizing side effects such as dysphagia or inability to belch or vomit.
During a panel discussion hosted by Implantica at the AFS meeting, the RefluxStop® treatment was presented in detail to an audience of over 120 surgeons, gastroenterologists, and other specialists. The session was moderated by Dr. John Lipham, a past president of AFS. He highlighted the significance of the FDA approval and the device's five-year clinical study results and European experience as a major advancement in GERD treatment.
Additionally, a recently published article detailing the RefluxStop® surgical approach was among the most trending papers at the meeting. Implantica's Founder and CEO, Peter Forsell, expressed satisfaction with the reception at the U.S. launch event, emphasizing the significant unmet need for GERD treatments in the United States, particularly for patients not adequately managed by medication.